Hospital-adapted inhaled phage therapy for ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae: a comparative pilot study
Authors' conclusion
This comparative pilot study outlines a translational approach from local K. pneumoniae epidemiology to hospital-adapted phage cocktails.
Study context
- Population
- Patients with ventilator-associated pneumonia (VAP) caused by multidrug-resistant Klebsiella pneumoniae (MDR-Kp)
- Participants
- 7 / 7 / 7
- Comparison
- Targeted phage therapy vs Non-targeted phage control vs Control
- Targeted phage therapyn = 7
- Non-targeted phage controln = 7
- Controln = 7reference
- Primary endpoint
- Microbiological eradication of any K. pneumoniae
- Follow-up
- Day 14
Methodological detailsprospective, single-centre, open-label, non-randomized
- Prospective
- Single-centre
- Open-label
- Non-randomized
Primary result
As reported in the abstract
Microbiological eradication of K. pneumoniae from respiratory samples
Secondary outcomes
Infection dynamics
- Targeted therapy associated with more rapid and consistent clearance
Vital signs and laboratory indices
- No significant between-group differences
Oxygenation (within-group, PT)
- Significant within-group improvement in oxygenation in PT, with earlier de-escalation of ventilatory support and antibiotic discontinuation
- P = 0.0247
Safety
- Inhaled phage well tolerated; no therapy-related adverse events
- 0
Original publication
Hospital-adapted inhaled phage therapy for ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae: a comparative pilot study. Crit Care. Published 13 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →